USSTOCK.TODAY
Pre-Market
Log in Sign up

Verastem Oncology shares surge 18% following release of early cancer treatment data

Barrons.com +1 ·

VSTM
VSTM Verastem Inc
$9.23 +19.71%
View chart & analysis →
RVMD -2.20%
  1. 1Verastem Oncology shares rose 18% on Wednesday.
  2. 2An objective response rate of 36% to 50% was confirmed in pancreatic cancer patients.
  3. 3Verastem Oncology announced a $250 million stock offering.

So what's the key point?

Verastem Oncology's stock price rose 18% after confirming the effectiveness of its cancer treatment. The company has decided to issue new shares in a $250 million offering.

Source Barrons.com +1 · View original ↗

Related 3-line summaries

Revolution Medicine Shares Fall 6% and Zealand Pharma Announces Clinical Results BioPharma Dive · 5d agoSLS draws attention on RVMD's pancreatic cancer drug approval; short-term focus on AML Barrons.com +1 · Aug 26Revolution Medicines' pancreatic cancer drug Raxonerib wins FDA approval…shares flat The New York Times +3 · Aug 26
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news